Cargando…
An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients
INTRODUCTION: Continuous delivery of levodopa–carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson’s disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations (“on” and “off” states). The MONOTREAT...
Autores principales: | Krüger, Rejko, Lingor, Paul, Doskas, Triantafyllos, Henselmans, Johanna M. L., Danielsen, Erik H., de Fabregues, Oriol, Stefani, Alessandro, Sensken, Sven-Christian, Parra, Juan Carlos, Onuk, Koray, Yegin, Ashley, Antonini, Angelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504221/ https://www.ncbi.nlm.nih.gov/pubmed/28631218 http://dx.doi.org/10.1007/s12325-017-0571-2 |
Ejemplares similares
-
The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
por: Pedersen, Stephen W, et al.
Publicado: (2017) -
Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
por: Catalán, Maria José, et al.
Publicado: (2017) -
Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017) -
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017) -
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)